EBioMedicine · 2026
Neuron-derived neurotrophic factor-positive interneurons: a cellular target for anti-seizure therapies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Richardson Amy, Mercier Marion S, Shimoda Yoshiteru, Graham Robert T, Leite Marco, Garcia Alejandro, Muller Maud, Bond Suraya A, Grozdanova Maria, Wu Qimin, Lieb Andreas, Kullmann Dimitri M, Magloire Vincent
Аннотация
BACKGROUND: Failure of epilepsy pharmacotherapy is common, justifying efforts to identify optimal cell targets for advanced therapies. Genetic manipulations of the inhibitory system in principle offer a finely tuned intervention that cannot be achieved with a broad reduction of pyramidal neuron excitability. In this context, neuron-derived neurotrophic factor-expressing (NDNF+) interneurons evoke long-lasting GABAA and GABAB receptor-mediated inhibition. However, their contribution to restraining hyperexcitability during epileptiform activity remains unexplored.
METHODS: To address this, we employed calcium imaging, optogenetics, and chemogenetics in an NDNF-Cre mouse line to investigate how NDNF+ interneurons influence cortical and hippocampal hyperactivity and spontaneous seizures.
FINDINGS: We show that NDNF+ interneurons are actively recruited during interictal spikes and focal seizures, although more slowly than parvalbumin-positive interneurons (mean difference: 2.8 s, p = 0.023). Optogenetic hyperpolarisation of NDNF+ interneurons exacerbates epileptic discharges (normalised seizure-duration mean difference: 0.23, p = 0.0474), whereas their depolarisation suppresses focal seizures, even when the optogenetic stimulus is delayed by several seconds from seizure onset (normalized seizure-duration mean difference: -0.27, p = 0.03). This effect is largely mediated by GABAB receptors. Additionally, chemogenetic depolarisation of NDNF+ interneurons has an important anti-seizure effect in the hippocampus both ex vivo (normalised seizure-duration mean difference: -0.92, p < 0.001) and in vivo.
INTERPRETATION: Collectively, these findings establish NDNF+ neurons as key regulators of both cortical and hippocampal excitability even during epileptic activity, and identify them as promising cellular targets for the development of anti-seizure therapies.
FUNDING: Epilepsy Research UK, Wellcome, the Medical Research Council, the Gatsby Charitable Foundation, and The Rosetrees Trust.
METHODS: To address this, we employed calcium imaging, optogenetics, and chemogenetics in an NDNF-Cre mouse line to investigate how NDNF+ interneurons influence cortical and hippocampal hyperactivity and spontaneous seizures.
FINDINGS: We show that NDNF+ interneurons are actively recruited during interictal spikes and focal seizures, although more slowly than parvalbumin-positive interneurons (mean difference: 2.8 s, p = 0.023). Optogenetic hyperpolarisation of NDNF+ interneurons exacerbates epileptic discharges (normalised seizure-duration mean difference: 0.23, p = 0.0474), whereas their depolarisation suppresses focal seizures, even when the optogenetic stimulus is delayed by several seconds from seizure onset (normalized seizure-duration mean difference: -0.27, p = 0.03). This effect is largely mediated by GABAB receptors. Additionally, chemogenetic depolarisation of NDNF+ interneurons has an important anti-seizure effect in the hippocampus both ex vivo (normalised seizure-duration mean difference: -0.92, p < 0.001) and in vivo.
INTERPRETATION: Collectively, these findings establish NDNF+ neurons as key regulators of both cortical and hippocampal excitability even during epileptic activity, and identify them as promising cellular targets for the development of anti-seizure therapies.
FUNDING: Epilepsy Research UK, Wellcome, the Medical Research Council, the Gatsby Charitable Foundation, and The Rosetrees Trust.